Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | plasmepsin X | 0.0244 | 0.0368 | 1 |
Toxoplasma gondii | eukaryotic aspartyl protease superfamily protein | 0.0244 | 0.0368 | 1 |
Loa Loa (eye worm) | aspartic protease BmAsp-2 | 0.0244 | 0.0368 | 1 |
Mycobacterium tuberculosis | Bifunctional enzyme MbtA: salicyl-AMP ligase (SAL-AMP ligase) + salicyl-S-ArCP synthetase | 0.1703 | 0.2776 | 1 |
Plasmodium vivax | plasmepsin IV, putative | 0.0244 | 0.0368 | 1 |
Schistosoma mansoni | subfamily A1A unassigned peptidase (A01 family) | 0.0244 | 0.0368 | 0.0368 |
Entamoeba histolytica | acyl-coA synthetase, putative | 0.0021 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin IX | 0.0244 | 0.0368 | 1 |
Schistosoma mansoni | cathepsin D (A01 family) | 0.0244 | 0.0368 | 0.0368 |
Leishmania major | acetyl-CoA synthetase, putative | 0.0021 | 0 | 0.5 |
Loa Loa (eye worm) | aspartic protease BmAsp-1 | 0.0244 | 0.0368 | 1 |
Plasmodium falciparum | plasmepsin VI | 0.0244 | 0.0368 | 1 |
Schistosoma mansoni | cathepsin D (A01 family) | 0.0244 | 0.0368 | 0.0368 |
Plasmodium falciparum | plasmepsin V | 0.0244 | 0.0368 | 1 |
Toxoplasma gondii | aspartyl protease ASP3 | 0.0244 | 0.0368 | 1 |
Brugia malayi | Eukaryotic aspartyl protease family protein | 0.0244 | 0.0368 | 1 |
Trypanosoma brucei | long-chain-fatty-acid-CoA ligase, putative | 0.0021 | 0 | 0.5 |
Schistosoma mansoni | subfamily A1A unassigned peptidase (A01 family) | 0.0244 | 0.0368 | 0.0368 |
Mycobacterium leprae | PROBABLE FATTY-ACID-CoA LIGASE FADD2 (FATTY-ACID-CoA SYNTHETASE) (FATTY-ACID-CoA SYNTHASE) | 0.0021 | 0 | 0.5 |
Schistosoma mansoni | subfamily A1A unassigned peptidase (A01 family) | 0.0244 | 0.0368 | 0.0368 |
Plasmodium vivax | plasmepsin V, putative | 0.0244 | 0.0368 | 1 |
Echinococcus granulosus | cathepsin d lysosomal aspartyl protease | 0.0244 | 0.0368 | 1 |
Leishmania major | 4-coumarate:coa ligase-like protein | 0.0021 | 0 | 0.5 |
Trypanosoma cruzi | acetyl-CoA synthetase, putative | 0.0021 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin IV | 0.0244 | 0.0368 | 1 |
Entamoeba histolytica | acyl-CoA synthetase, putative | 0.0021 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0244 | 0.0368 | 1 |
Schistosoma mansoni | subfamily A1A unassigned peptidase (A01 family) | 0.0244 | 0.0368 | 0.0368 |
Brugia malayi | aspartic protease BmAsp-2, identical | 0.0244 | 0.0368 | 1 |
Toxoplasma gondii | aspartyl proteinase (eimepsin), putative | 0.0244 | 0.0368 | 1 |
Brugia malayi | hypothetical protein | 0.0244 | 0.0368 | 1 |
Plasmodium vivax | aspartyl protease, putative | 0.0244 | 0.0368 | 1 |
Plasmodium falciparum | plasmepsin II | 0.0244 | 0.0368 | 1 |
Leishmania major | 4-coumarate:coa ligase-like protein | 0.0021 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin VII | 0.0244 | 0.0368 | 1 |
Onchocerca volvulus | 0.0244 | 0.0368 | 1 | |
Loa Loa (eye worm) | hypothetical protein | 0.0244 | 0.0368 | 1 |
Loa Loa (eye worm) | aspartyl protease 6 | 0.0244 | 0.0368 | 1 |
Plasmodium vivax | aspartyl protease, putative | 0.0244 | 0.0368 | 1 |
Schistosoma mansoni | subfamily A1A unassigned peptidase (A01 family) | 0.0244 | 0.0368 | 0.0368 |
Brugia malayi | hypothetical protein | 0.0244 | 0.0368 | 1 |
Trypanosoma cruzi | long-chain-fatty-acid-CoA ligase, putative | 0.0021 | 0 | 0.5 |
Plasmodium vivax | aspartyl protease, putative | 0.0244 | 0.0368 | 1 |
Entamoeba histolytica | acyl-CoA synthetase, putative | 0.0021 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin III | 0.0244 | 0.0368 | 1 |
Leishmania major | acetyl-CoA synthetase, putative | 0.0021 | 0 | 0.5 |
Toxoplasma gondii | aspartyl protease ASP1 | 0.0244 | 0.0368 | 1 |
Mycobacterium leprae | POSSIBLE O-SUCCINYLBENZOIC ACID--CoA LIGASE MENE (OSB-CoA SYNTHETASE) (O-SUCCINYLBENZOATE-CoA SYNTHASE) | 0.0021 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0244 | 0.0368 | 1 |
Mycobacterium leprae | PROBABLE FATTY-ACID-CoA LIGASE FADD7 (FATTY-ACID-CoA SYNTHETASE) (FATTY-ACID-CoA SYNTHASE) | 0.0021 | 0 | 0.5 |
Schistosoma mansoni | subfamily A1A unassigned peptidase (A01 family) | 0.0244 | 0.0368 | 0.0368 |
Onchocerca volvulus | 0.0244 | 0.0368 | 1 | |
Schistosoma mansoni | subfamily A1A unassigned peptidase (A01 family) | 0.0244 | 0.0368 | 0.0368 |
Brugia malayi | Pepsin A precursor | 0.0244 | 0.0368 | 1 |
Leishmania major | 4-coumarate:coa ligase-like protein | 0.0021 | 0 | 0.5 |
Plasmodium vivax | aspartyl proteinase, putative | 0.0244 | 0.0368 | 1 |
Leishmania major | long-chain-fatty-acid-CoA ligase, putative | 0.0021 | 0 | 0.5 |
Mycobacterium leprae | POSSIBLE FATTY-ACID-CoA LIGASE FADD10 (FATTY-ACID-CoA SYNTHETASE) (FATTY-ACID-CoA SYNTHASE) | 0.0021 | 0 | 0.5 |
Mycobacterium ulcerans | bifunctional enzyme MbtA: salicyl-AMP ligase (SAL-AMP ligase) + salicyl-S-ACP synthetase | 0.1703 | 0.2776 | 1 |
Entamoeba histolytica | long-chain-fatty-acid--CoA ligase, putative | 0.0021 | 0 | 0.5 |
Trypanosoma cruzi | acetyl-CoA synthetase, putative | 0.0021 | 0 | 0.5 |
Schistosoma mansoni | subfamily A1A unassigned peptidase (A01 family) | 0.0244 | 0.0368 | 0.0368 |
Mycobacterium leprae | Probable fatty-acid-CoA synthetase FadD22 (fatty-acid-CoA ligase) (fatty-acid-CoA synthase) | 0.0021 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin VIII, putative | 0.0244 | 0.0368 | 1 |
Echinococcus multilocularis | cathepsin d (lysosomal aspartyl protease) | 0.0244 | 0.0368 | 1 |
Trypanosoma cruzi | long-chain-fatty-acid-CoA ligase, putative | 0.0021 | 0 | 0.5 |
Brugia malayi | aspartic protease BmAsp-1, identical | 0.0244 | 0.0368 | 1 |
Schistosoma mansoni | subfamily A1A unassigned peptidase (A01 family) | 0.0244 | 0.0368 | 0.0368 |
Toxoplasma gondii | aspartyl protease | 0.0244 | 0.0368 | 1 |
Trichomonas vaginalis | Clan AA, family A1, cathepsin D-like aspartic peptidase | 0.0244 | 0.0368 | 1 |
Plasmodium vivax | aspartyl proteinase, putative | 0.0244 | 0.0368 | 1 |
Trypanosoma brucei | acetyl-CoA synthetase, putative | 0.0021 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin I | 0.0244 | 0.0368 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI50 (functional) | -4.619 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.492 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.485 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.445 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.267 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.177 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.138 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.105 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.048 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.